Literature DB >> 7719272

Liposomes as delivery systems in the prevention and treatment of infectious diseases.

J J Bergers1, T L ten Hagen, E W van Etten, I A Bakker-Woudenberg.   

Abstract

Research on the potential application of liposomes in the prevention and treatment of infectious diseases has focussed on improvement of the therapeutic index of antimicrobial drugs and immunomodulators and on stimulation of the immune response to otherwise weak antigens in vaccines composed of purified micro-organism subunits. In this review current approaches in this field are outlined. The improved therapeutic index of antimicrobial drugs after encapsulation in liposomes is a result of enhanced drug delivery to infected tissue or infected cells and/or a reduction of drug toxicity of potentially toxic antibiotics. Liposomal encapsulation of immunomodulators that activate macrophages aims at reducing the toxicity of these agents and targeting them to the cells of the mononuclear phagocyte system in order to increase the nonspecific resistance of the host against infections. Studies on the immunogenicity of liposomal antigens have demonstrated that liposomes can potentiate the humoral and cell mediated immunity to a variety of antigens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7719272     DOI: 10.1007/bf01875551

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  83 in total

Review 1.  Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens.

Authors:  C R Alving
Journal:  Biochim Biophys Acta       Date:  1992-12-11

2.  Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes.

Authors:  I N Mbawuike; P R Wyde; P M Anderson
Journal:  Vaccine       Date:  1990-08       Impact factor: 3.641

3.  Effect of liposome encapsulation on antigen presentation in vitro. Comparison of presentation by peritoneal macrophages and B cell tumors.

Authors:  P Dal Monte; F C Szoka
Journal:  J Immunol       Date:  1989-03-01       Impact factor: 5.422

4.  Targeting of drug loaded immunoliposomes to herpes simplex virus infected corneal cells: an effective means of inhibiting virus replication in vitro.

Authors:  S G Norley; L Huang; B T Rouse
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

5.  Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer.

Authors:  P J Creaven; J W Cowens; D E Brenner; B M Dadey; T Han; R Huben; C Karakousis; H Frost; D LeSher; J Hanagan
Journal:  J Biol Response Mod       Date:  1990-10

6.  Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model.

Authors:  S Zeng; C Hu; H Wei; Y Lu; Y Zhang; J Yang; G Yun; W Zou; B Song
Journal:  Ophthalmology       Date:  1993-11       Impact factor: 12.079

7.  Liposomes in topical drug delivery.

Authors:  H E Schaeffer; D L Krohn
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-02       Impact factor: 4.799

8.  Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice.

Authors:  E W van Etten; C van den Heuvel-de Groot; I A Bakker-Woudenberg
Journal:  J Antimicrob Chemother       Date:  1993-11       Impact factor: 5.790

9.  Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome)--a report on 40 cases from a single centre.

Authors:  R Chopra; A Fielding; A H Goldstone
Journal:  Leuk Lymphoma       Date:  1992

Review 10.  Liposomes in the treatment of malignancy: a clinical perspective.

Authors:  S M Sugarman; R Perez-Soler
Journal:  Crit Rev Oncol Hematol       Date:  1992       Impact factor: 6.312

View more
  5 in total

1.  Enhanced intramacrophage activity of resorcinomycin A against Mycobacterium avium-Mycobacterium intracellulare complex after liposome encapsulation.

Authors:  R Gomez-Flores; R Hsia; R Tamez-Guerra; R T Mehta
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

Review 2.  Advanced and controlled drug delivery systems in clinical disease management.

Authors:  J R Brouwers
Journal:  Pharm World Sci       Date:  1996-10

3.  Prophylactic role of liposomized chloroquine against murine cryptococcosis less susceptible to fluconazole.

Authors:  Masood A Khan; Rukhsana Jabeen; Owais Mohammad
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

4.  Encapsulation of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in liposomes prepared by thin film hydration and their transfer to mesenchymal stem cells and cord blood hematopoietic stem cells.

Authors:  Sławomir Lewicki; Monika Leśniak; Agnieszka Sobolewska-Ruta; Aneta Lewicka; Marta Grodzik; Eugeniusz K Machaj; Marek Saracyn; Jacek Z Kubiak; Zygmunt Pojda
Journal:  Arch Med Sci       Date:  2020-04-18       Impact factor: 3.707

5.  Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct.

Authors:  A Roth; F Rohrbach; R Weth; B Frisch; F Schuber; W S Wels
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.